Compare RECT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RECT | NEUP |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | Singapore | United States |
| Employees | 111 | 8 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 23.0M |
| IPO Year | N/A | N/A |
| Metric | RECT | NEUP |
|---|---|---|
| Price | $1.48 | $4.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 2.3K | ★ 38.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $3.65 |
| 52 Week High | $4.98 | $21.31 |
| Indicator | RECT | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 58.34 |
| Support Level | $1.30 | $3.92 |
| Resistance Level | $1.94 | $4.56 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 40.31 | 52.55 |
Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.